SCHEMBL3562948

SCHEMBL3562948

Cc1ccc([N+](=O)[O-])cc1Nc1cc(-c2cccnc2)ncn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.47
CYP3A4 P08684 5/20 0.47
CYP2D6 P10635 4/20 0.47
HSD17B10 Q99714 4/20 0.47
CLK4 Q9HAZ1 4/20 0.47
ALDH1A1 P00352 3/20 0.47
ABL1 P00519 3/20 0.47
BCR P11274 3/20 0.47
CYP2C19 P33261 2/20 0.47
PRKCA P17252 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
EGFR P00533 1/20 0.47
SRC P12931 1/20 0.47
CCNT1 O60563 4/20 0.47
CDK9 P50750 4/20 0.47
TSHR P16473 1/20 0.44
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3564749 0.90 ALDH1A1 (0.49) ALDH1A1MEN1KMT2ACCNT1CDK9
SCHEMBL783033 0.87 MAPK10 (0.49) ALDH1A1ABL1BCRPRKCAEGFR
SCHEMBL4266541 0.84 ALDH1A1 (0.49) ALDH1A1ABL1BCRPRKCAMEN1
SCHEMBL4264785 0.84 KARS1 (0.54) ALDH1A1ABL1BCRPRKCAMEN1
SCHEMBL3565337 0.81 ABL1 (0.66) CYP1A2CYP3A4CYP2D6HSD17B10CLK4
SCHEMBL29364396 0.81 ABL1 (0.69) ABL1BCRPRKCAEGFRSRC
SCHEMBL1550 0.81 ABL1 (0.69) ABL1BCRPRKCAEGFRSRC
Water SCHEMBL28827802 0.81 ABL1 (0.68) ABL1BCRPRKCAEGFRSRC
SCHEMBL4262443 0.80 ABL1 (0.55) ALDH1A1ABL1BCRPRKCAMEN1
SCHEMBL4276994 0.80 ALDH1A1 (0.48) ALDH1A1ABL1BCRPRKCAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3299358-A1 AMIDE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2018-03-28 EP disclosed
EP-1702917-B1 AMIDE DERIVATIVE AND MEDICINE NIPPON SHINYAKU CO LTD (JP) 2017-08-02 EP disclosed
US-7728131-B2 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia NIPPON SHINYAKU CO., LTD. (JP) 2010-06-01 US disclosed
US-20080293940-A1 Amide Derivative and Medicine NIPPON SHINYAKU CO., LTD. (JP) 2008-11-27 US disclosed
EP-1702917-A1 AMIDE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2006-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293940-A1 Amide Derivative and Medicine ABL2, ABL1, BCR CYP1A2 212/4885CYP3A4 1294/4885CYP2D6 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.